Zhou F, Huang Y, Cai W, et al. - In the Chinese population, researchers sought to determine the genomic as well as the immunologic profiles of pure pulmonary sarcomatoid carcinoma (PSC). Using surgical specimens of 58 pure PSCs, experts conducted next-generation sequencing analysis of a panel of 1,021 genes. TP53 (74%, 43/58), KRAS (24%, 14/58), SMARCA4 (14%, 8/58), MET (12%, 7/58), EGFR (10%, 6/58), MLL4 (10%, 6/58), NF1 (10%, 6/58), NOTCH4 (10%, 6/58), and TERT (10%, 6/58) were identified as the top mutational genes of pure PSC. The median tumor mutational burden (TMB) was estimated to be 8.6 mutations/Mb (megabase). In TP53-mutant tumors vs wild-type tumors, a higher median TMB was noted. In this cohort, at least one actionable alteration was present in 45% of patients with pure PSC. The presence of either MSI (microsatellite instability)-H, PD-L1-positive, or high-TMB tumors, was evident in more than 60% of patients (65.5%, 38/58), and for these, survival benefits from immune checkpoint inhibitors might be seen.